知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1379 条记录 (耗时 0.055 秒)

    Tumor antigen
    91.
    发明申请
    Tumor antigen 有权
    肿瘤抗原

    公开(公告)号：US20070066804A1

    公开(公告)日：2007-03-22

    申请号：US11543088

    申请日：2006-10-05

    申请人： Kyogo Itoh

    发明人： Kyogo Itoh

    IPC分类号： C07K16/30 ,  C07K14/82 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06

    CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K2039/53 ,  C07K14/47

    摘要： Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

    摘要翻译： 通过识别HLA-A2和肿瘤抗原肽而激活的HLA-A2限制性肿瘤特异性细胞毒性T淋巴细胞和衍生自肿瘤抗原的肽或多肽的肿瘤抗原诱导和/或激活的HLA-A2限制性肿瘤特异性细胞毒性T淋巴细胞， 提供其互补链多核苷酸，包含包含该多核苷酸的重组载体的转化体。

    Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
    98.
    发明申请
    Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes 审中-公开
    用于选择和产生掺入所述选择的表位的T细胞肽表位和疫苗的方法

    公开(公告)号：US20070025968A1

    公开(公告)日：2007-02-01

    申请号：US11085749

    申请日：2005-03-21

    申请人： Sjoerd Van Der Burg ,  Wijbe Kast ,  Reinaldus Toes ,  Rienk Offringa ,  Cornelius Melief

    发明人： Sjoerd Van Der Burg ,  Wijbe Kast ,  Reinaldus Toes ,  Rienk Offringa ,  Cornelius Melief

    IPC分类号： A61K48/00 ,  A61K39/00 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C12N15/861

    CPC分类号： G01N33/56977

    摘要： The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T cell epitopes. These vaccines find their application in many fields ranging from cancer treatments to treatments of prophylaxis of infectious diseases such as Aids. The present invention provides novel methods for selecting the peptide sequences from an intact antigen which will lead to a proper (T cell) immune response upon administration in a suitable vehicle. The epitopes and vaccines are, of course, also part of the present invention.

    摘要翻译： 本发明涉及分子生物学和免疫学领域。 特别地，本发明涉及用于提供疫苗的疫苗和方法，其在施用于哺乳动物，特别是人时可引起免疫应答。 优选的引发免疫应答是由肽T细胞表位引起的T细胞应答。 这些疫苗可用于许多领域，从癌症治疗到预防感染性疾病如艾滋病的治疗。 本发明提供了从完整抗原中选择肽序列的新方法，该合适的抗原将在合适的载体中施用后导致适当的（T细胞）免疫应答。 当然，表位和疫苗也是本发明的一部分。

    Truncated proteins as cancer markers
    99.
    发明申请
    Truncated proteins as cancer markers 有权
    截断的蛋白质作为癌症标志物

    公开(公告)号：US20070020706A1

    公开(公告)日：2007-01-25

    申请号：US11446420

    申请日：2006-06-02

    申请人： George Gorodeski ,  Ying-Hong Feng ,  Xin Li

    发明人： George Gorodeski ,  Ying-Hong Feng ,  Xin Li

    IPC分类号： G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K16/30 ,  C07K14/82

    CPC分类号： C07K16/30 ,  C07K14/4747 ,  C07K14/4748 ,  C07K14/705 ,  G01N33/57492

    摘要： Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2X7 protein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2X7 in cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2X7 in cells are described.

    摘要翻译： 公开了用于检测和/或治疗癌症或潜在癌症的方法/试剂。 在一个实施方案中，描述了用于检测细胞中P2X 7蛋白的截短形式的方法和试剂。 在一个实施方案中，描述了用于增加细胞中全长P2X 7 N的量和/或活性的方法和试剂。 在一个实施方案中，描述了用于降低细胞中截短的P2X 7的量和/或活性的方法和试剂。

    Prlz regulatory elements in the treatment of disease and the discovery of therapeutics
    100.
    发明申请
    Prlz regulatory elements in the treatment of disease and the discovery of therapeutics 审中-公开
    Prlz调节因素治疗疾病和发现治疗

    公开(公告)号：US20070015149A1

    公开(公告)日：2007-01-18

    申请号：US10510148

    申请日：2003-04-07

    申请人： Ruoxing Wang ,  Leland W. K. Chung

    发明人： Ruoxing Wang ,  Leland W. K. Chung

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C07K16/30 ,  C40B30/06

    CPC分类号： C07K14/4702 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/82 ,  C07K16/3069 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011

    摘要： The compositions and methods of the present invention are based, in part, on a gene designated prostate leucine zipper (PrLZ) and the sequences that mediate its expression. The presence of the leucine zipper indicates that PrLZ encodes a protein that interacts with other proteins. Methods to inhibit the activity of PrLZ by identifying and inhibiting the interaction between PrLZ and such binding partners are within the scope of the invention, as are methods of inhibiting PrLZ in other ways (by, for example, inhibiting its expression with antisense molecules or siRNAs or inhibiting its activity with, for example, anti-PrLZ antibodies). Such inhibition is useful in the treatment of cancers or dysplasias affecting PrLZ-positive tissues, such as those in the prostate.

    摘要翻译： 本发明的组合物和方法部分地基于称为前列腺亮氨酸拉链（PrLZ）的基因和介导其表达的序列。 亮氨酸拉链的存在表明PrLZ编码与其他蛋白质相互作用的蛋白质。 通过鉴定和抑制PrLZ与这种结合配偶体之间的相互作用来抑制PrLZ的活性的方法也在本发明的范围内，以其他方式抑制PrLZ的方法也是如此（例如通过用反义分子或siRNA抑制其表达 或用例如抗PrLZ抗体抑制其活性）。 这种抑制可用于治疗影响PrLZ阳性组织（例如前列腺中的那些）的癌症或发育不良。